We are thrilled to announce the successful completion of the Pivotal BE Study for Semaglutide 1.34mg/ml pre-filled pen, a product developed in collaboration with one of our strategic partners.
Our generic and bioequivalent version of Ozempic is indicated for the treatment of type II Diabetes. The brand sold $17.9bn globally in 2022, according to IQVIA.
This achievement marks a significant milestone in our journey towards creating a high-value portfolio of complex products, including peptide injections. Our Semaglutide development is set to become a true landmark, highlighting our expertise in developing cutting-edge therapies.
In addition to Semaglutide, Adalvo is one of the few companies having an extensive offering of both small molecule and peptide treatment possibilities for type 2 diabetes, as depicted below.
Partner up now!
At Adalvo, there are no half measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
ajish.rajan@adalvo.com – Central & Eastern Europe, Russia & CIS
jose.rendueles@adalvo.com- North Europe, APAC, MENA & Israel
margarida.neves@adalvo.com – Brazil
marta.puig@adalvo.com - LATAM (exc. Brazil) & South Europe
paulo.rodriguez@adalvo.com – Europe
supreet.sharma@adalvo.com – UK/Ireland, North America & South Africa
arni.baldursson@adalvo.com - Head of Global BD&L
Disclaimer: Products which are subject to patent protection are currently not offered or made available in countries where patents are in force.